The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer - Takeaways - MDSpire

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer

  • By

  • Qiang Yang

  • Shaobin Wang

  • Fanlin Liu

  • Yongli Yu

  • Hai Zhao

  • June 1, 2026

  • 0 min

Share

  • 1

    Cancer immunotherapy has shifted the focus from traditional treatments to strategies that enhance the immune system's ability to combat tumors.

  • 2

    CAR-T therapy, TIL therapy, and TCEs are the three main modalities of T cell-driven therapies in cancer treatment.

  • 3

    CAR-T therapy has shown significant success in hematologic malignancies but struggles with solid tumors due to a hostile tumor microenvironment.

  • 4

    TIL therapy utilizes naturally selected T cells from tumors but faces challenges in biomanufacturing and tumor immunogenicity.

  • 5

    The future of cancer treatment may lie in combining these therapies with genetic engineering and TME-modulating agents to enhance efficacy.

Original Source(s)

The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer

  • by Qiang Yang, Shaobin Wang, Fanlin Liu, Yongli Yu, Hai Zhao

  • June 1, 2026

Related Content

Total ureteral replacement with a small intestinal graft as a reconstructive stage of combined treatment for recurrent colorectal cancer: case report

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

Impact of the clonal architecture and probable biallelic inactivation of TET2 mutations in myelodysplastic neoplasms